Celldex Therapeutics, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Celldex Therapeutics, Inc. (CLDX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $3.50 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2024-02-26
- Celldex Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Celldex Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-09-30 was $3.50M.
- Celldex Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-12-31 was $14.50M.
- Celldex Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-09-30 was $0.00.
- Celldex Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $3.50M, a 80.56% decline from fiscal 2020.
- Celldex Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $18.00M.
- Celldex Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $18.68M, a 43.67% increase from fiscal 2017.
- Celldex Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $13.00M.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month as first filed | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $3.50M derived: sum of 2 quarters · filed 2024-02-26 | $3.50M 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $3.50M 10-Q · filed 2022-11-09 | $3.50M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $14.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $14.50M derived: sum of 2 quarters · filed 2023-02-28 | $18.00M derived: sum of 3 quarters · filed 2023-02-28 | $18.00M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.50M derived: sum of 2 quarters · filed 2021-11-09 | $3.50M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $3.50M 10-Q · filed 2021-08-05 | $3.50M 10-Q · filed 2021-08-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $6.88M derived: sum of 3 quarters · filed 2021-03-29 | $18.68M 10-K · filed 2021-03-29 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $6.88M derived: sum of 2 quarters · filed 2019-11-12 | $18.68M 10-Q · filed 2019-11-12 | $18.68M derived: sum of 4 quarters · filed 2020-03-26 | |
| 2018-06-30 | $6.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $18.68M 10-Q · filed 2018-08-08 | $18.68M derived: sum of 3 quarters · filed 2020-03-26 | $31.68M derived: sum of 4 quarters · filed 2020-03-26 | |
| 2018-03-31 | $11.80M 10-Q · filed 2018-11-07 | $18.68M 10-Q · filed 2018-05-10 | $11.80M derived: sum of 2 quarters · filed 2020-03-26 | $24.80M derived: sum of 3 quarters · filed 2020-03-26 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $13.00M derived: sum of 2 quarters · filed 2020-03-26 | $13.00M 10-K · filed 2020-03-26 | ||
| 2017-09-30 | $13.00M 10-Q · filed 2018-11-07 | $13.00M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |